144 related articles for article (PubMed ID: 7882335)
41. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors.
Zariwala M; Liu E; Xiong Y
Oncogene; 1996 Jan; 12(2):451-5. PubMed ID: 8570224
[TBL] [Abstract][Full Text] [Related]
42. Expression of p16(INK4A) induces dominant suppression of glioblastoma growth in situ through necrosis and cell cycle arrest.
Hung KS; Hong CY; Lee J; Lin SK; Huang SC; Wang TM; Tse V; Sliverberg GD; Weng SC; Hsiao M
Biochem Biophys Res Commun; 2000 Mar; 269(3):718-25. PubMed ID: 10720483
[TBL] [Abstract][Full Text] [Related]
43. Complex structure and regulation of the P16 (MTS1) locus.
Stone S; Jiang P; Dayananth P; Tavtigian SV; Katcher H; Parry D; Peters G; Kamb A
Cancer Res; 1995 Jul; 55(14):2988-94. PubMed ID: 7606716
[TBL] [Abstract][Full Text] [Related]
44. A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
Schmid M; Sen M; Rosenbach MD; Carrera CJ; Friedman H; Carson DA
Oncogene; 2000 Nov; 19(50):5747-54. PubMed ID: 11126361
[TBL] [Abstract][Full Text] [Related]
45. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
[TBL] [Abstract][Full Text] [Related]
46. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
47. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.
Koh J; Enders GH; Dynlacht BD; Harlow E
Nature; 1995 Jun; 375(6531):506-10. PubMed ID: 7777061
[TBL] [Abstract][Full Text] [Related]
48. Induction of senescence in human malignant glioma cells by p16INK4A.
Uhrbom L; Nistér M; Westermark B
Oncogene; 1997 Jul; 15(5):505-14. PubMed ID: 9247304
[TBL] [Abstract][Full Text] [Related]
49. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
[TBL] [Abstract][Full Text] [Related]
50. The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor.
Raffel C; Ueki K; Harsh GR; Louis DN
Neurosurgery; 1995 May; 36(5):971-4; discussion 974-5. PubMed ID: 7791990
[TBL] [Abstract][Full Text] [Related]
51. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway.
Arap W; Knudsen E; Sewell DA; Sidransky D; Wang JY; Huang HJ; Cavenee WK
Oncogene; 1997 Oct; 15(17):2013-20. PubMed ID: 9366518
[TBL] [Abstract][Full Text] [Related]
52. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.
Arap W; Knudsen ES; Wang JY; Cavenee WK; Huang HJ
Oncogene; 1997 Feb; 14(5):603-9. PubMed ID: 9053859
[TBL] [Abstract][Full Text] [Related]
53. Allelotype analysis in mouse hepatocellular carcinomas; frequent homozygous deletion of mouse homolog of p16/CDKN2 gene on chromosome 4 in culture.
Miyasaka K; Fukui T; Kitagawa T
Biol Pharm Bull; 1996 May; 19(5):683-91. PubMed ID: 8741575
[TBL] [Abstract][Full Text] [Related]
54. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.
Otterson GA; Khleif SN; Chen W; Coxon AB; Kaye FJ
Oncogene; 1995 Sep; 11(6):1211-6. PubMed ID: 7566983
[TBL] [Abstract][Full Text] [Related]
55. CDKN2 (MTS1/p16INK4A) gene alterations in hematological malignancies.
Uchida T; Kinoshita T; Saito H; Hotta T
Leuk Lymphoma; 1997 Feb; 24(5-6):449-61. PubMed ID: 9086436
[TBL] [Abstract][Full Text] [Related]
56. Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method.
Rawnsley JD; Srivatsan ES; Chakrabarti R; Billings KR; Wang MB
Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):863-7. PubMed ID: 9260553
[TBL] [Abstract][Full Text] [Related]
57. Absence of p16 gene (CDKN2) deletions in microdissected primary breast carcinoma specimens.
Calvano JE; Rush EB; Tan LK; Rosen PP; Borgen PI; Van Zee KJ
Ann Surg Oncol; 1997; 4(5):416-20. PubMed ID: 9259969
[TBL] [Abstract][Full Text] [Related]
58. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Gruis NA; Weaver-Feldhaus J; Liu Q; Frye C; Eeles R; Orlow I; Lacombe L; Ponce-Castaneda V; Lianes P; Latres E
Am J Pathol; 1995 May; 146(5):1199-206. PubMed ID: 7747814
[TBL] [Abstract][Full Text] [Related]
59. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
Merlo A; Herman JG; Mao L; Lee DJ; Gabrielson E; Burger PC; Baylin SB; Sidransky D
Nat Med; 1995 Jul; 1(7):686-92. PubMed ID: 7585152
[TBL] [Abstract][Full Text] [Related]
60. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.
Bartsch D; Shevlin DW; Tung WS; Kisker O; Wells SA; Goodfellow PJ
Genes Chromosomes Cancer; 1995 Nov; 14(3):189-95. PubMed ID: 8589035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
